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Abstract
Transfusional iron overload is a major cause of morbidity and mortality in thalassemia, 
sickle-cell disease and other chronic anemias. To overcome these problems, orally bio available 
iron chelators, deferiprone and deferasirox, were used for the treatment of patients suffer-
ing from thalassemia. The interactions between deferiprone and deferasirox with the carrier 
protein, B-thalassemia hemoglobin (Hb), were investigated using fluorescence, circular 
dichroism (CD) and UV-visible measurements at physiological condition.
Strong fluorescence quenching on interactions of the above drugs with B-thalassemia Hb 
were observed. Fluorescence quenching data of thalassemia Hb in the presence of defera-
sirox have shown greater affinity of binding. The number of binding sites to Hb for defera-
sirox was found to be more relative to those of the deferiprone. The effects of these drugs 
on the oxygen affinity of the thalassemia Hb were studied by spectroscopic methods using 
sodium dithionite. Results indicated that deferiprone reduces oxygen affinity (increases 
oxygen releasing ability) of Hb, while in the presence of deferasirox, oxygen affinity of 
Hb has significantly increased by dose-dependent manner. As such, deferasirox exhibited 
opposite effect relative to deferiprone on the function of thalassemia Hb. In clinical dose of 
deferiprone, CD results showed that, the A-helical content of thalassemia Hb significantly 
increased. By use of the clinical dose of deferasirox, however, a decrease in A-helical con-
tent of protein was observed, which resulted in decreasing stability of thalassemia Hb. Our 
study showed that reduction in stability of thalassemia Hb in the presence of deferasirox 
induced higher conformational changes in protein.
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